Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial
Open Access
- 1 March 2012
- journal article
- research article
- Published by Elsevier BV in The American Journal of Clinical Nutrition
- Vol. 95 (3), 678-685
- https://doi.org/10.3945/ajcn.111.024786
Abstract
Background: Skeletal abnormalities have been reported in HIV-infected children and adolescents. Although the etiology is not well understood, vitamin D deficiency may be involved. Objective: The study objective was to evaluate the effect of vitamin D and calcium supplementation on bone mass accrual in HIV-infected youth. Design: Perinatally HIV-infected children were randomly assigned to receive vitamin D (100,000 IU cholecalciferol given every 2 mo) and calcium (1 g/d) (supplemented group) or double placebo (placebo group) for 2 y. The total-body bone mineral content (TBBMC), total-body bone mineral density (TBBMD), spine bone mineral content (SBMC), and spine bone mineral density (SBMD) were assessed by using dual-energy X-ray absorptiometry at baseline and at 2 annual follow-up visits. Results: Fifty-nine participants, aged 6–16 y, were randomly assigned to either the supplemented (n = 30) or the placebo (n = 29) group. At enrollment, supplemented and placebo groups did not differ with respect to age, sex, dietary intakes of vitamin D and calcium, mean baseline serum 25-hydroxyvitamin D [25(OH)D] concentration, TBBMC, TBBMD, SBMC, or SBMD. Significant increases in serum 25(OH)D were observed in the supplemented group but not in the placebo group. TBBMC, TBBMD, SBMC, and SBMD increased significantly at 1 and 2 y in both groups. No between-group differences were observed at any time before or after adjustment for stage of sexual maturation by mixed linear model analysis. Conclusion: One gram of calcium per day and oral cholecalciferol at a dosage of 100,000 IU every 2 mo administered to HIV-infected children and adolescents did not affect bone mass accrual despite significant increases in serum 25(OH)D concentrations. This trial was registered at clinicaltrials.gov as NCT00724178.This publication has 60 references indexed in Scilit:
- Effect of Bimonthly Supplementation With Oral Cholecalciferol on Serum 25-Hydroxyvitamin D Concentrations in HIV-Infected Children and AdolescentsPEDIATRICS, 2009
- HIV Protease Inhibitors Selectively Induce Gene Expression Alterations Associated with Reduced Calcium Deposition in Primary Human OsteoblastsAIDS Research and Human Retroviruses, 2007
- Bone and Body Composition of Children and Adolescents With Repeated Forearm FracturesJournal of Bone and Mineral Research, 2005
- Estimates of optimal vitamin D statusOsteoporosis International, 2005
- HIV-1 Vpr enhances production of receptor of activated NF-?B ligand (RANKL) via potentiation of glucocorticoid receptor activityArchiv für die gesamte Virusforschung, 2004
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Prevalence of Severe Hypovitaminosis D in Patients With Persistent, Nonspecific Musculoskeletal PainMayo Clinic Proceedings, 2003
- Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus–Infected IndividualsClinical Infectious Diseases, 2003
- Variations in the Pattern of Pubertal Changes in BoysArchives of Disease in Childhood, 1970
- Variations in pattern of pubertal changes in girls.Archives of Disease in Childhood, 1969